In reply to 'discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome'

American Journal of Kidney Diseases

Volumn 65, Issue 2, 2015, Pages 342-343

  Ardissino, Gianluigi ^a   Possenti, Ilaria ^a   Tel, Francesca ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; ECULIZUMAB; MONOCLONAL ANTIBODY;

CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG WITHDRAWAL; GENE MUTATION; HEMOLYTIC UREMIC SYNDROME; HUMAN; LETTER; MAINTENANCE THERAPY; RELAPSE; REMISSION; RISK FACTOR; THROMBOTIC THROMBOCYTOPENIC PURPURA; COST OF ILLNESS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEMOGLOBINURIA; MALE; QUALITY OF LIFE; TREATMENT WITHDRAWAL;

ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; COST OF ILLNESS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEMOGLOBINURIA; HUMANS; MALE; QUALITY OF LIFE; WITHHOLDING TREATMENT;

EID: 84921497498     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2014.05.028     Document Type: Letter

References (2)

1. J.F.M. Wetzels, and N.C.A.J. van de Kar Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome Am J Kidney Dis 65 2 2015 342
2. G. Ardissino, S. Testa, and I. Possenti Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases Am J Kidney Dis 64 4 2014 633 637